Adenosine A2B receptors: a novel therapeutic target in asthma?

doi:10.1016/S0165-6147(98)01179-1

Trends in Pharmacological Sciences

Volume 19, Issue 4, 1 April 1998, Pages 148-153

https://doi.org/10.1016/S0165-6147(98)01179-1 Get rights and content

Abstract

Adenosine is an endogenous nucleoside that modulates many physiological processes. Its actions are mediated by interaction with specific cell membrane receptors. Four subtypes of adenosine receptor have been cloned: A1, A2A, A2B and A3. Significant advancement has been made in our understanding of the molecular pharmacology and physiological relevance of adenosine receptors but our knowledge of A2B receptors lags behind that of other receptor types. Only recently have potentially important functions been discovered for the A2B receptors, prompting a renewed interest in this receptor type. A2B receptors have been implicated in the regulation of vascular smooth muscle tone, cell growth, intestinal function and neurosecretion. In this review, Igor Feoktistov, Riccardo Polosa, Stephen Holgate and Italo Biaggioni focus on the role of A2B receptors in mast cell activation and the potential relevance of this action on asthma.

Section snippets

Acknowledgements

Ackowledgements

The authors' work is supported by NIHgrants R29HL55596, 1PO1HL56693 and RR00095, and a British Medical Research Council Programme Grant No. PG-860-4034.

References (75)

E. Ongini et al.
Trends Pharmacol. Sci.
(1996)
H. Clarke et al.
Pulm. Pharmacol.
(1989)
N. Crimi
J. Allergy Clin. Immunol.
(1989)
L.E. Gustafsson et al.
Eur. J. Pharmacol.
(1986)
R. Polosa et al.
J. Allergy Clin. Immunol.
(1991)
V. Ramkumar et al.
J. Biol. Chem.
(1993)
D.L. Marquardt et al.
Biochem. Pharmacol.
(1990)
B.B. Fredholm et al.
Eur. J. Pharmacol.
(1982)
D. Ukena et al.
Eur. J. Pharmacol.
(1985)
C.G. Persson et al.
Life Sci.
(1986)

D. Ukena et al.

FEBS Lett.

(1986)

B.B. Fredholm

Gen. Pharmacol.

(1997)

D.J. Mogul et al.

Neuron

(1993)

Belardinelli, L. and Pelleg, A. (1995) Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative...

M.J. Cushley et al.

Br. J. Clin. Pharmacol.

(1983)

J.S. Mann et al.

J. Appl. Physiol.

(1986)

N. Crimi

Allergy

(1988)

J.S. Mann et al.

Br. J. Clin. Pharmacol.

(1985)

I. Feoktistov et al.

J. Clin. Invest.

(1995)

S.T. Holgate et al.

Ann. New York Acad. Sci.

(1991)

P.T. Peachell et al.

Am. Rev. Respir. Dis.

(1988)

G.D. Phillips et al.

Thorax

(1987)

P. Rafferty et al.

Am. Rev. Respir. Dis.

(1987)

N. Crimi

Eur. Respir. J.

(1995)

G.D. Phillips et al.

Am. Rev. Respir. Dis.

(1990)

R. Polosa

Am. J. Respir. Crit. Care Med.

(1995)

N. Crimi et al.

Drug Dev. Res.

(1993)

R. Polosa

J. Allergy Clin. Immunol.

(1994)

R. Pauwels et al.

Am. Rev. Respir. Dis.

(1987)

N. Crimi et al.

Eur. Respir. J.

(1992)

S. Manzini et al.

Br. J. Pharmacol.

(1990)

R. Polosa et al.

Eur. Respir. J.

(1992)

A.G. Driver et al.

Am. Rev. Respir. Dis.

(1993)

D.L. Marquardt et al.

Proc. Natl. Acad. Sci. U. S. A.

(1984)

J.L. Madara

J. Clin. Invest.

(1993)

A.H. Watt et al.

Br. J. Clin. Pharmacol.

(1987)

F.R. Rose et al.

J. Exp. Med.

(1988)

Cited by (185)

Identification of new potent A<inf>1</inf> adenosine receptor antagonists using a multistage virtual screening approach
2020, European Journal of Medicinal Chemistry
Citation Excerpt :
In contrast, activation of A2A and A2B ARs stimulates adenylyl cyclase activity followed by an increased concentration of cAMP with an opposing effect [3]. The changes in adenosine levels are believed to closely correlate with certain kinds of physiopathological states such as psychosis and anxiety, neurodegenerative disorders, asthma and inflammatory diseases [6,7]. Moreover, selective agonists and antagonists are generally considered to be potential candidates in numerous therapeutic applications by modulating adenosine receptor-induced physiopathological processes.
The use of antagonists for each adenosine receptor (AR) subtype as potent clinical candidates is of growing interest due to their involvement in the treatment of various diseases. The recent resolution of several A₁ and A_2A ARs X-ray structures provides opportunities for structure-based drug design. In this study, we describe the discovery of novel A₁AR antagonists by applying a multistage virtual screening approach, which is based on random forest (RF), e-pharmacophore modeling and docking methods. A multistage virtual screening approach was applied to screen the ChemDiv library (1,492,362 compounds). Among the final hits, 22 compounds were selected for further radioligand binding assay analysis against human A₁AR, and 18 compounds (81.82% success) exhibited nanomolar or low micromolar binding potency (K_i). Then, we selected six compounds (pK_i > 6) to further evaluate their antagonist profile in a cAMP functional assay, and we found that they had low micromolar antagonistic activity (pIC₅₀ = 5.51–6.38) for the A₁AR. Particularly, four of six compounds (pK_i > 6) showed very good affinity (pK_i = 6.11–7.13) and selectively (>100-fold) for A₁AR over A_2AAR. Moreover, the novelty analysis suggested that four of six compounds (pK_i > 6) were dissimilar to existing A₁AR antagonists and hence represented novel A₁AR antagonists. Further molecular docking and molecular dynamics (MD) studies showed that the three selective compounds 15, 20 and 22 were stabilized (RMS_lig value ≤ 2 Å) inside the binding pocket of A₁AR with similar orientations to the docking pose in 100-ns MD simulations, whereas they escaped from the binding area of A_2AAR with larger values of RMS_lig (RMS_lig ≥ 2 Å). We hope that these findings provide new insights into the discovery of drugs targeting A₁AR and facilitate research on new drugs and treatments for A₁AR-related human pathologies.
Functional characterization of a novel adenosine A<inf>2B</inf> receptor agonist on short-term plasticity and synaptic inhibition during oxygen and glucose deprivation in the rat CA1 hippocampus
2019, Brain Research Bulletin
Adenosine is an endogenous neuromodulator exerting its biological functions via four receptor subtypes, A₁, A_2A, A_2B, and A₃. A_2B receptors (A_2BRs) are expressed at hippocampal level where they are known to inhibit paired pulse facilitation (PPF), whose reduction reflects an increase in presynaptic glutamate release. The effect of A_2BRs on PPF is known to be sensitive not only to A_2BR blockade but also to the A₁R antagonist DPCPX, indicating that it involves A₁R activation. In this study we provide the first functional characterization of the newly synthesized non-nucleoside like A_2BR agonist P453, belonging to the amino-3,5-dicyanopyridine series. By extracellular electrophysiological recordings, we demonstrated that P453 mimicked the effect of the prototypical A_2BR agonist BAY60-6583 in decreasing PPF at Schaffer collateral-CA1 synapses in rat acute hippocampal slices. This effect was prevented by two different A_2BR antagonists, PSB603 and MRS1754, and by the A₁R antagonist DPCPX. We also investigated the functional role of A_2BR during a 2 min of oxygen and glucose deprivation (OGD) insult, known to produce a reversible fEPSP inhibition due to adenosine A₁R activation. We found that P453 and BAY60-6583 significantly delayed the onset of fEPSP reduction induced by OGD and the effect was blocked by PSB603.
We conclude that P453 is a functional A_2BR agonist whose activation decreases PPF by increasing glutamate release at presynaptic terminals and delays A₁R-mediated fEPSP inhibition during a 2-minute OGD insult.
Repurposing drugs as inhaled therapies in asthma
2018, Advanced Drug Delivery Reviews
For the first 40 years of the 20th century treatment for asthma occurred in response to an asthma attack. The treatments were given by injection or orally and included the adrenergic agonists adrenalin/epinephrine and ephedrine and a phosphodiesterase inhibitor theophylline. Epinephrine became available as an aerosol in 1930. After 1945, isoprenaline, a non-selective beta agonist, became available for oral use but it was most widely used by inhalation. Isoprenaline was short-acting with unwanted cardiac effects. More selective beta agonists, with a longer duration of action and fewer side-effects became available, including orciprenaline in 1967, salbutamol in 1969 and terbutaline in 1970. The inhaled steroid beclomethasone was available by 1972 and budesonide by 1982. Spirometry alone and in response to exercise was used to assess efficacy and duration of action of these drugs for the acute benefits of beta₂ agonists and the chronic benefits of corticosteroids. Early studies comparing oral and aerosol beta₂ agonists found equivalence in bronchodilator effect but the aerosol treatment was superior in preventing exercise-induced bronchoconstriction. Inhaled drugs are now widely used including the long-acting beta₂ agonists, salmeterol and formoterol, and the corticosteroids, fluticasone, ciclesonide, mometasone and triamcinolone, that act locally and have low systemic bio-availability. Repurposing drugs as inhaled therapies permitted direct delivery of low doses of drug to the site of action reducing the incidence of unwanted side-effects and permitting the prophylactic treatment of asthma.
Mitogen-activated protein kinases as therapeutic targets for asthma
2017, Pharmacology and Therapeutics
Corticosteroid-resistant asthmatics, although comprising only a portion of the asthma population, account for most of the morbidity, mortality and economic burden associated with asthma. Moreover, corticosteroids are not effective inhibitors of airway remodeling changes, and their long-term use is associated with debilitating systemic side effects. Therefore, potent and safe novel therapeutic alternatives, targeting basic pathophysiological mechanisms responsible for the severe asthmatic phenotype are urgently needed. Mitogen-activated protein kinases (MAPKs) are ubiquitously expressed signaling enzymes that are involved in almost all aspects of the asthmatic inflammatory network; as such, they represent an emerging target for the treatment of asthma. This paper provides a rationale for targeting MAPKs in the treatment of asthma by reviewing the in vitro evidence of its relevance to asthma pathogenesis. This is followed by discussing the results of MAPK inhibition in pre-clinical models of asthma. Finally, the potential safety concerns regarding MAPK inhibition in human disease, as well as the future prospects for its clinical development are explored. In conclusion, this review underlines the promising results of MAPK inhibition in animal asthma models especially in restoring corticosteroid sensitivity, as well as recent clinical safety and efficacy evidence obtained from trials in similar disease areas such as COPD, and of course, the paucity of clinical evidence for targeting MAPKs in asthma. Based on this review, a more rigorous effort for clinical development of MAPK inhibitors in asthma is justified.
A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm
2017, Toxicology and Applied Pharmacology
Adenosine contributes to the pathophysiology of respiratory disease, and adenosine challenge leads to bronchospasm and dyspnoea in patients. The equilibrative nucleoside transporter 1 (ENT1) terminates the action of adenosine by removal from the extracellular environment. Therefore, it is proposed that inhibition of ENT1 in respiratory disease patients leads to increased adenosine concentrations, triggering bronchospasm and dyspnoea. This study aims to assess the translation of in vitro ENT1 inhibition to the clinical incidence of bronchospasm and dyspnoea in respiratory disease, cardiovascular disease and healthy volunteer populations. Four marketed drugs with ENT1 activity were assessed; dipyridamole, ticagrelor, draflazine, cilostazol. For each patient population, the relationship between in vitro ENT1 [³H]-NBTI binding affinity (K_i) and [³H]-adenosine uptake (IC₅₀) to the incidence of: (1) bronchospasm/severe dyspnoea; (2) tolerated dyspnoea and; (3) no adverse effects, was evaluated. A high degree of ENT1 inhibition (≥ 13.3x K_i, ≥ 4x IC₅₀) associated with increased incidence of bronchospasm/severe dyspnoea for patients with respiratory disease only, whereas a lower degree of ENT1 inhibition (≥ 0.1x K_i, ≥ 0.05x IC₅₀) associated with a tolerable level of dyspnoea in both respiratory and cardiovascular disease patients. ENT1 inhibition had no effect in healthy volunteers. Furthermore, physicochemical properties correlative with ENT1 binding were assessed using a set of 1625 diverse molecules. Binding to ENT1 was relatively promiscuous (22% compounds K_i < 1 μM) especially for neutral or basic molecules, and greater incidence tracked with higher lipophilicity (clogP > 5). This study rationalises inclusion of an assessment of ENT1 activity during early safety profiling for programs targeting respiratory disorders.
Design and synthesis of novel xanthine derivatives as potent and selective A<inf>2B</inf> adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases
2017, European Journal of Medicinal Chemistry
Citation Excerpt :
Adenosine has been shown to cause mast cell degranulation [10], vasodilation [11], chloride secretion in epithelial cells [12,13], growth inhibition of smooth muscle cells [14], and stimulation of glucose production in rat hepatocytes [15] and stimulate VEGF secretion [16] via activation of A2BAdoR. A2BAdoR antagonists, therefore, can potentially be used as therapeutic agents for the treatment of asthma and chronic obstructive pulmonary disease [4,17–19] type II diabetes [15], cystic fibrosis [12], inflammatory bowel disease [13] and cancer [20]. Adenosine induces bronchoconstriction in asthmatic patients but not in normal people [21,22].
Adenosine induces bronchial hyperresponsiveness and inflammation in asthmatics through activation of A_2B adenosine receptor (A_2BAdoR). Selective antagonists have been shown to attenuate airway reactivity and improve inflammatory conditions in pre-clinical studies. Hence, the identification of novel, potent and selective A_2BAdoR antagonist may be beneficial for the potential treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). Towards this effort, we explored several prop-2-ynylated C8-aryl or heteroaryl substitutions on xanthine chemotype and found that 1-prop-2-ynyl-1H-pyrazol-4-yl moiety was better tolerated at the C8 position. Compound 59, exhibited binding affinity (K_i) of 62 nM but was non-selective for A_2BAdoR over other AdoRs. Incorporation of substituted phenyl on the terminal acetylene increased the binding affinity (K_i) significantly to <10 nM. Various substitutions on terminal phenyl group and different alkyl substitutions on N-1 and N-3 were explored to improve the potency, selectivity for A_2BAdoR and the solubility. In general, compounds with meta-substituted phenyl provided better selectivity for A_2BAdoR compared to that of para-substituted analogs. Substitutions such as basic amines like pyrrolidine, piperidine, piperazine or cycloalkyls with polar group were tried on terminal acetylene, keeping in mind the poor solubility of xanthine analogs in general. However, these substitutions led to a decrease in affinity compared to compound 59. Subsequent SAR optimization resulted in identification of compound 46 with high human A_2BAdoR affinity (K_i = 13 nM), selectivity against other AdoR subtypes and with good pharmacokinetic properties. It was found to be a potent functional A_2BAdoR antagonist with a K_i of 8 nM in cAMP assay in hA_2B-HEK293 cells and an IC₅₀ of 107 nM in IL6 assay in NIH-3T3 cells. Docking study was performed to rationalize the observed affinity data. Structure-activity relationship (SAR) studies also led to identification of compound 36 as a potent A_2BAdoR antagonist with K_i of 1.8 nM in cAMP assay and good aqueous solubility of 529 μM at neutral pH. Compound 46 was further tested for in vivo efficacy and found to be efficacious in ovalbumin-induced allergic asthma model in mice.

View all citing articles on Scopus

View full text

Trends in Pharmacological Sciences

Adenosine A2B receptors: a novel therapeutic target in asthma?

Abstract

Section snippets

Acknowledgements

Trends Pharmacol. Sci.

Pulm. Pharmacol.

J. Allergy Clin. Immunol.

Eur. J. Pharmacol.

J. Allergy Clin. Immunol.

J. Biol. Chem.

Biochem. Pharmacol.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Life Sci.

FEBS Lett.

Gen. Pharmacol.

Neuron

Br. J. Clin. Pharmacol.

J. Appl. Physiol.

Allergy

Br. J. Clin. Pharmacol.

J. Clin. Invest.

Ann. New York Acad. Sci.

Am. Rev. Respir. Dis.

Thorax

Am. Rev. Respir. Dis.

Eur. Respir. J.

Am. Rev. Respir. Dis.

Am. J. Respir. Crit. Care Med.

Drug Dev. Res.

J. Allergy Clin. Immunol.

Am. Rev. Respir. Dis.

Eur. Respir. J.

Br. J. Pharmacol.

Eur. Respir. J.

Am. Rev. Respir. Dis.

Proc. Natl. Acad. Sci. U. S. A.

J. Clin. Invest.

Br. J. Clin. Pharmacol.

J. Exp. Med.